Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

Morel, Sandra [UCL] Lévy, Frédéric [LICR Lausanne] Burlet-Schiltz, Odile [Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse Cédex, France] Brasseur, Francis [UCL] Probst-Kepper, Michael [UCL] Peitrequin, Anne-Lise [LICR Lausanne] Monsarrat, Bernard [Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse Cédex, France] Van Velthoven, Robert [Département d'Urologie, Institut Bordet, Bruxelles] Cerottini, Jean-Charles [LICR Lausanne] Boon, Thierry [UCL] Gairin, Jean-Edouard [Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse Cédex, France] Van den Eynde, Benoît [UCL] et al.[show all]

By stimulating human lymphocytes with an autologous renal carcinoma, we obtained CTL recognizing an antigen derived from a novel, ubiquitous protein. The CTL failed to lyse autologous EBV-transformed B cells, even though the latter express the protein. This is due to the presence in these cells of immunoproteasomes, which, unlike standard proteasomes, cannot produce the antigenic peptide. We show that dendritic cells also carry immunoproteasomes and fail to present this antigen. This may explain why the relevant CTL escape thymic deletion and are not regularly activated in the periphery. Lack of cleavage by the immunoproteasome was also observed for melanoma differentiation antigen Melan-A26-35/HLA-A2, currently used for antitumoral vaccination. For immunization with such antigens, proteins should be less suitable than peptides, which do not require proteasome digestion in dendritic cells.